Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
NCT00446329 · Papageorgiou General Hospital · PHASE4 · terminated · last registry update 2014-10-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “due to financial problems” | – | Registry record, Papageorgiou General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CASR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-10-29Results posted on the registry: Wake Forest University Health Sciences, cinacalcet hydrochloride (NCT01054079)
- 2015-09-15Phase 3 first posted: Kyowa Kirin Co., Ltd., KHK7580 + KRN1493 (NCT02549391)
- 2015-08-17Phase 3 first posted: Brigham and Women's Hospital, eplerenone + amiloride (NCT02525796)
- 2015-05-15Results posted on the registry: Amgen, cinacalcet capsule + placebo (NCT01277510)
- 2015-01-19Phase 3 first posted: Amgen, Cinacalcet (NCT02341417)
- 2014-05-15Phase 3 first posted: Amgen, Cinacalcet HCl (NCT02138838)
- 2014-04-25Results posted on the registry: Amgen, Traditional Vitamin D Therapy + Cinacalcet (NCT01181531)
- 2014-04-02Phase 3 first posted: Amgen, Etelcalcetide (NCT02102204)
- 2014-03-12Results posted on the registry: Amgen, Cinacalcet + Vitamin D (NCT00803712)
- 2014-01-22Results posted on the registry: Amgen, Cinacalcet + Placebo (NCT00345839)
- 2013-12-04Results posted on the registry: Amgen, Sensipar (Cinacalcet HCl) (NCT00261950)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision